Document is current
Any future updates will be listed below
-
Authors
Shimoda, Masami https://orcid.org/0000-0001-5758-739X
Hoshikawa, Kaori https://orcid.org/0000-0002-5982-5619
Oda, Shinri https://orcid.org/0000-0001-9170-5732
Imai, Masaaki https://orcid.org/0000-0003-4294-7190
Aoki, Rie https://orcid.org/0000-0002-9615-4332
Shinohara, Chiaki https://orcid.org/0009-0003-5186-5776
- License Information
-
More Information
Article History
Received: 7 August 2025
Accepted: 31 December 2025
First Online: 6 January 2026
Declarations
:
: The authors declare no competing interests.
: All study protocols were approved by the Institutional Review Board for Clinical Research (approval no. 22R-078) and the Conflict of Interest Management Committee (approval no. 22–168) at our university. The study protocol was implemented in accordance with the 1964 Declaration of Helsinki and its later amendments, and all patients provided written informed consent before participating in the study. For all migraine patients, written informed consent for participation was obtained for the prospective study of data acquired during routine medical treatments on the basis of national legislation and institutional requirements. Our report complies with the “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE) statement for cohort studies.
: All participants in the study consented to publication of the data obtained in relation to the present study.
: A previous version of this paper was published as a preprint titled “MRI-ASL-based CBF changes during the interictal period after anti-CGRP therapy in migraine patients” 33 .
